AUTHORS
Daisuke Araki, MD, Andre Larochelle, MD, PhD2
AFFILIATIONS
1 Laboratory of Regenerative Therapies for Inherited Blood Disorders, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
2 Laboratory of Regenerative Therapies for Inherited Blood Disorders, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
ABSTRACT
Background. The thrombopoietin (TPO)-cMPL axis is a central regulator of hematopoietic stem cell (HSC) maintenance. We recently showed that high surface cMPL expression alone enriches functional long-term HSCs (LT-HSCs) from adult human bone marrow (BM) and mobilized peripheral blood (MPB) CD34⁺ cells (Araki et al., Blood 2025). Within the immunophenotypic HSC/multipotent progenitor (MPP) compartment (CD34⁺CD38⁻CD45RA⁻), CD90 (Thy-1) is the canonical positive marker used to enrich human LT-HSCs and a defining component of the CD90⁺CD49f⁺ LT-HSC phenotype (Notta et al., Science 2011). We previously reported that operationally defined cMPLhigh cells (top 20%) within the CD34+CD38-CD45RA- HSC/MPP compartment showed superior, durable, clonally balanced multilineage repopulation relative to size-matched CD90high counterpart (top 20%) (Araki et al, ASH 2025). Because those comparisons used separately defined, size-matched fractions, two questions remained unresolved: how cMPL and CD90 co-distribute within CD34⁺CD38⁻CD45RA⁻ cells, and whether cMPL provides functional discriminatory value beyond CD90.
Co-expression analysis. Across four independent MPB donors, we used flow cytometry to gate on CD34⁺CD38⁻CD45RA⁻ populations and then applied two orthogonal sub-fractionations: CD90⁺ vs CD90⁻, and cMPLhigh vs cMPLlow (top and bottom 20% of cMPL). Co-enrichment was bidirectional but asymmetric. cMPL was modestly higher in CD90⁺ than CD90⁻ cells (MFI 1.29-fold; cMPLhigh frequency 27% vs 13%, P = 0.002). The reciprocal relationship was stronger: CD90 was markedly higher in cMPLhigh than cMPLlow cells (MFI 2.31-fold; CD90⁺ frequency 68% vs 33%, P = 0.0068). The cMPLhighCD90⁺ population thus represents the most stringently HSC-enriched immunophenotypic fraction, and stratification by cMPL resolved CD90 status more sharply than the reverse.
Functional validation. We prospectively sorted four subsets (cMPLlowCD90⁺, cMPLlowCD90⁻, cMPLhighCD90⁺, and cMPLhighCD90⁻), defining cMPLhigh and cMPLlow as the top and bottom 20% within each CD90 fraction, and transplanted equal numbers (5×10³) into NBSGW mice (n = 8-10/group), tracking peripheral blood (PB) human chimerism (human CD45 frequency) at 6, 12, and 16 weeks. Within the cMPLlow cohort, engraftment kinetics did not significantly differ by CD90 status (t-test on Δweek16 - week6, P = 0.28), despite diverging mean trends (CD90⁺ cells rose from 1.1% to 2.2% while CD90⁻ cells declined from 1.9% to 0.88%). Conversely, within the cMPLhigh cohort, CD90⁺ and CD90⁻ cells engrafted comparably (8.5% and 11% at 16 weeks; P = 0.44) and both markedly exceeded their cMPLlow counterparts (P = 0.0013). BM analysis at 16 weeks corroborated PB findings, with comparable multilineage (CD13+ myeloid, CD20+ B-cell, and CD3+ T-cell) output irrespective of CD90 status.
Conclusions. cMPL and CD90 are mutually enriched and their co-expression (cMPLhighCD90⁺) marks the most stringently enriched LT-HSC fraction within the CD34⁺CD38⁻CD45RA⁻ HSC/MPP compartment. Critically, high cMPL identifies cells with durable repopulating activity independent of CD90: a cMPLhighCD90⁻ fraction, discarded by canonical CD90-based selection, contains functional LT-HSCs, whereas CD90 status does not rescue repopulation among cMPLlow cells. cMPL therefore adds functional value beyond CD90 and merits incorporation into human HSC purification strategies, with implications for basic human HSC biology and human HSC-directed therapeutic development.
DISCLOSURES
Daisuke Araki, MD: No relevant conflicts of interest to declare.